- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07223606
Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
October 31, 2025 updated by: ProgenaBiome
This study uses fecal microbiota transplant (FMT) to correct gut microbiome dysbiosis prior to and during standard-of-care neuroblastoma treatment
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Detailed Description
Patients with neurobastoma and concurrent dysbiosis showing a bifidobacteria-bacteroides gap will undergo fecal microbiota transplant as an adjunctive to standard-of-care oncology treatment.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Ventura, California, United States, 93003
- ProgenaBiome
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- willingness of parent/guardian to sign ICF
- diagnosis of neuroblastoma
- dysbiosis of the gut microbiome
Exclusion Criteria:
- parent/guardian unwilling to sign ICF
- dysbiosis does not show a bifidobaceteria-bacteroides gap
- severely abnormal screening lab values
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
September 18, 2025
First Submitted That Met QC Criteria
October 31, 2025
First Posted (Estimated)
November 3, 2025
Study Record Updates
Last Update Posted (Estimated)
November 3, 2025
Last Update Submitted That Met QC Criteria
October 31, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroectodermal Tumors, Primitive, Peripheral
- Neuroectodermal Tumors, Primitive
- Pathological Conditions, Signs and Symptoms
- Dysbiosis
- Neuroblastoma
Other Study ID Numbers
- IND 31935 (Other Identifier: FDA)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.